http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-042521-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44e0905262f429c7590b40df8448c0c5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 |
| filingDate | 2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-042521-A1 |
| titleOfInvention | SUBSTITUTED 5-AMINOMETIL-1H-PIRROL-2-CARBOXYL ACID AMIDES |
| abstract | This refers to substituted 5-aminomethyl-1H-pyrrol-2-carboxylic acid amides, process for their preparation and medicaments containing these compounds. Claim 1: Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid amides according to the general formula (1) wherein: R1 represents H, a linear or branched aliphatic moiety, saturated or unsaturated, if at least mono-substituted, a cycloaliphatic, saturated or unsaturated moiety, if necessary at least monosubstituted, presenting at least one heteroatom as a member of the ring, being linked, if appropriate, through an alkylene group, if at least monosubstituted, an aryl moiety or heteroaryl if necessary at least monosubstituted, or an aryl or heteroaryl moiety, if appropriate at least monosubstituted, linked through an alkylene group, if substituted; R2 represents an aliphatic, linear or branched, saturated or unsaturated moiety, if at least given monosubstituted, a cycloaliphatic, saturated or unsaturated moiety, if at least given monosubstituted, if necessary presenting at least one heteroatom as a member of the ring, being if necessary linked through an alkylene group, if appropriate monosubstituted, an aryl or heteroaryl moiety, if at least given monosubstituted, or an aryl or heteroaryl moiety, if at least given monosubstituted, linked through an alkylene group , if substituted, or R1 and R2, together with the N atom that binds them as a member of the ring, form a saturated or unsaturated cycloaliphatic moiety, presenting at least one other heteroatom as a member of the ring, and if necessary given at least monosubstituted; R3 represents an aryl or heteroaryl moiety, if at least given monosubstituted, an ester group or a carboxy group; R4 and R5, the same or different, represent H, a linear or branched, saturated or unsaturated aliphatic moiety, if at least given monosubstituted, a cycloaliphatic, saturated or unsaturated moiety, if at least given monosubstituted, presenting at least given case a heteroatom as a member of the ring, where appropriate linked through an alkylene group, if necessary at least monosubstituted, an aryl or heteroaryl moiety, if at least given monosubstituted, or an aryl or heteroaryl moiety, if appropriate less monosubstituted, linked through an alkylene group, if any substituted, or R4 and R5, together with the N atom that binds them as ring members, form a saturated or unsaturated cycloaliphatic moiety, presenting at least one other case heteroatom as a member of the ring, if at least given monosubstituted, and R6 represents a linear or branched aliphatic moiety, saturated or unsaturated, if at least given monosubstituted, a cycloalif moiety Attic, saturated or unsaturated, if necessary at least monosubstituted, presenting at least one heteroatom as a member of the ring, if necessary linked through an alkylene group, if at least monosubstituted, an aryl or heteroaryl moiety , if necessary at least monosubstituted, or an aryl or heteroaryl moiety, if at least given monosubstituted, linked through an alkylene group, if at least given monosubstituted, if appropriate in the form of its pure stereoisomers, especially enantiomers or diastereomers, their racemates or in the form of mixtures of stereoisomers, especially enantiomers, diastereomers or rotamers, in any proportion of mixture, or respectively in the form of their acids or bases or in the form of their salts, especially physiologically acceptable salts, or respectively in the form of their solvates, especially hydrates. Claim 41: Use of at least one substituted 5-aminomethyl-1H-pyrrol-2-carboxylic acid amide according to one of claims 1-9 for the preparation of a medicament for pain control, preferably acute pain and / or pain Chronic and 7th neuropathic pain. Claim 42: Use of at least one substituted 5-aminomethyl-1H-pyrrol-2-carboxylic acid amide according to one of claims 1-9 for the preparation of a medicament for the treatment of withdrawal symptoms, memory disorders, neurodegenerative diseases, preferably Morbus Parkinson, Morbus Huntington or Morbus Alzheimer, epilepsy, cardiovascular disorders, water retention diseases, intestinal motility (diarrhea), urinary incontinence, anorexia, tinnitus, pruritus, depressions, sexual dysfunctions, preferably dysfunction erectile, respiratory tract diseases, or for anxiolysis, for diuresis, for the inhibition of the urination reflex, for the regulation, preferably stimulation, of food intake, for the reduction of the addictive potential of opioids, of preferred form of morphine, for the modulation of motor activity, for the influence of the cardiovascular system, for ma preferred for vasodilation of the arteries, for the regulation of the ORL-1 receptor, for the inhibition of norepinephrine uptake or for the inhibition of the uptake of 5-hydroxytryptamine- (5-HT). |
| priorityDate | 2002-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.